Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 5/20 | 0.38 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18188282 | 0.79 | PTK2B (0.59) | ULK1KIF11SYKPTK2B | |
| SCHEMBL7697294 | 0.76 | CA12 (0.47) | DRD2DRD4JAK2TYK2 | |
| SCHEMBL18188436 | 0.73 | MKNK1 (0.53) | ULK1PTK2B | |
| SCHEMBL29542975 | 0.73 | MKNK1 (0.53) | ULK1PTK2B | |
| SCHEMBL18196416 | 0.71 | TRPA1 (0.44) | — | |
| SCHEMBL7899032 | 0.71 | FGFR2 (0.38) | ULK1PTK2BDRD2DRD4JAK2 | |
| SCHEMBL13730254 | 0.70 | MAPT (0.44) | SYK | |
| SCHEMBL18188356 | 0.68 | KIF11 (0.54) | KIF11SYK | |
| SCHEMBL28163783 | 0.68 | CA12 (0.58) | DRD2DRD4 | |
| SCHEMBL18188119 | 0.68 | JAK1 (0.46) | SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-04-26 | — | — | US | disclosed |
| CN-107835814-B | Azabenzimidazoles and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | ULK1 2005/4885S1PR1 1347/4885KIF11 2735/4885 |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | ULK1 2005/4885S1PR1 1347/4885KIF11 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.